Sera Prognostics (NASDAQ:SERA) CEO Sells $85,773.60 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 28,215 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $3.04, for a total transaction of $85,773.60. Following the completion of the transaction, the chief executive officer directly owned 768,081 shares in the company, valued at $2,334,966.24. This represents a 3.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Zhenya Lindgardt also recently made the following trade(s):

• On Thursday, September 11th, Zhenya Lindgardt sold 3,246 shares of Sera Prognostics stock. The stock was sold at an average price of $3.13, for a total value of $10,159.98.

Sera Prognostics Stock Up 10.7%

Shares of SERA stock traded up $0.33 on Wednesday, hitting $3.40. The stock had a trading volume of 121,326 shares, compared to its average volume of 29,844. Sera Prognostics, Inc. has a one year low of $1.37 and a one year high of $9.13. The company has a market cap of $131.24 million, a PE ratio of -4.42 and a beta of 0.97. The business has a 50 day moving average price of $3.18 and a 200 day moving average price of $2.79.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.03. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.10 million. Sera Prognostics had a negative net margin of 34,343.16% and a negative return on equity of 41.69%. Equities research analysts expect that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sera Prognostics in a research note on Monday. Wall Street Zen upgraded shares of Sera Prognostics from a “sell” rating to a “hold” rating in a report on Saturday, October 25th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Hedge Funds Weigh In On Sera Prognostics

A number of hedge funds have recently made changes to their positions in the company. Abel Hall LLC acquired a new stake in shares of Sera Prognostics in the second quarter worth approximately $31,000. Wagner Wealth Management LLC purchased a new position in Sera Prognostics in the 2nd quarter valued at $34,000. Riverview Capital Advisers LLC acquired a new stake in Sera Prognostics during the 2nd quarter worth $35,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Sera Prognostics during the third quarter worth $38,000. Finally, XTX Topco Ltd acquired a new stake in shares of Sera Prognostics in the first quarter valued at about $39,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.